Anticoagulation Forum/LinkedIn
Sep 5, 2025, 12:55
RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
Anticoagulation Forum shared on LinkedIn:
”Missed it live? The recording of our recent webinar ‘Secondary VTE Prevention: To Reduce or Not to Reduce? A Focus on RENOVE and API-CAT‘ is now available!
Watch it now on our Archived Webinars page.
Dive into one of the most debated questions in anticoagulation—when and how to reduce the dose.
Our expert panel breaks down results from the RENOVE and API-CAT trials, with practical insights you can apply in your practice right away.
What you’ll take away:
- DOAC dosing strategies for extended secondary VTE prevention
- Evidence-based guidance for individualized care
- Real-world tips from leading clinicians
Free for AC Forum members — and joining is quick and free.
Don’t miss the chance to catch up on this timely and dynamic discussion!”
Watch the webinar here.
Find the latest webinars and seminars on thrombosis featured in Hemostasis Today.
-
Jan 27, 2026, 14:06Dmitrii V Kalinin Shares A PhD Opportunity: Hardiman Scholarship
-
Jan 27, 2026, 13:48Filippo Cademartiri: 3 Biomarkers Are Better Than 1: Refining ASCVD Risk in MESA
-
Jan 27, 2026, 12:27Martin Haluzík on Residual Cardiovascular Risk in Coronary Artery Disease
-
Jan 27, 2026, 12:18Stuart Phillips: Strong Bodies Are Good, Informed Bodies Are Better!
-
Jan 27, 2026, 12:07Daniel Torrent: This Should Be An Ice Cold Take… But Veins Aren’t Arteries
-
Jan 27, 2026, 09:17Paolo Zamboni on CCSVI Associated to Multiple Sclerosis
-
Jan 27, 2026, 09:02Rowan Paul: Platelet Dose Determines Success in PRP Therapy
-
Jan 27, 2026, 08:48Uriel Suárez: Hemi‐Orolingual Angioedema in a Patient With VEXAS Syndrome
-
Jan 27, 2026, 08:23Rossella Crescitelli on Platelets’ and PEVs’ Association with Lung Cancer Metastases